Research programme: hepatitis C virus nucleotide polymerase inhibitors - Inhibitex

Drug Profile

Research programme: hepatitis C virus nucleotide polymerase inhibitors - Inhibitex

Alternative Names: HCV nucleotide polymerase inhibitors - Inhibitex; INX-189 back-up compound - Inhibitex; INX-189 follow-on compound - Inhibitex

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Inhibitex
  • Class Nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA
  • 14 Feb 2012 Inhibitex has been acquired by Bristol-Myers Squibb
  • 12 Jan 2011 Preclinical trials in Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top